دورية أكاديمية
Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States.
| العنوان: | Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States. |
|---|---|
| المؤلفون: | Mojica MF; Department of Molecular Biology and Microbiology, Case Western Reserve University , Cleveland, Ohio, USA.; Research Service, Veterans Affairs Northeast Ohio Healthcare System , Cleveland, Ohio, USA.; CASE-VA Center for Antimicrobial Resistance and Epidemiology , Cleveland, Ohio, USA., Zeiser ET; Research Service, Veterans Affairs Northeast Ohio Healthcare System , Cleveland, Ohio, USA., Becka SA; Research Service, Veterans Affairs Northeast Ohio Healthcare System , Cleveland, Ohio, USA., LiPuma JJ; University of Michigan , Ann Arbor, Michigan, USA., Six DA; Venatorx Pharmaceuticals, Inc. , Malvern, Pennsylvania, USA., Moeck G; Venatorx Pharmaceuticals, Inc. , Malvern, Pennsylvania, USA., Papp-Wallace KM; Research Service, Veterans Affairs Northeast Ohio Healthcare System , Cleveland, Ohio, USA.; Department of Medicine, Case Western Reserve University , Cleveland, Ohio, USA.; Department of Biochemistry, Case Western Reserve University , Cleveland, Ohio, USA. |
| المصدر: | Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2023 Nov 15; Vol. 67 (11), pp. e0049823. Date of Electronic Publication: 2023 Sep 28. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington, American Society for Microbiology |
| مواضيع طبية MeSH: | Burkholderia gladioli* , Burkholderia cepacia complex* , Cystic Fibrosis*/microbiology, Humans ; United States ; Cefepime/pharmacology ; Anti-Bacterial Agents/pharmacology ; beta-Lactamase Inhibitors/pharmacology ; beta-Lactamases ; Microbial Sensitivity Tests |
| مستخلص: | The novel clinical-stage β-lactam-β-lactamase inhibitor combination, cefepime-taniborbactam, demonstrates promising activity toward many Gram-negative bacteria producing class A, B, C, and/or D β-lactamases. We tested this combination against a panel of 150 Burkholderia cepacia complex (Bcc) and Burkholderia gladioli strains. The addition of taniborbactam to cefepime shifted cefepime minimum inhibitory concentrations toward the provisionally susceptible range in 59% of the isolates tested. Therefore, cefepime-taniborbactam possessed similar activity as first-line agents, ceftazidime and trimethoprim-sulfamethoxazole, supporting further development. Competing Interests: D.A.S. and G.M. are employees of Venotorx Pharmaceuticals, Inc. Venatorx Pharmaceuticals, Inc., provided funding as a research grant to K.M.P-W. to conduct this study. |
| معلومات مُعتمدة: | United Kingdom WT_ Wellcome Trust; HHSN272201300019C United States AI NIAID NIH HHS; HHSN272201300019I United States AI NIAID NIH HHS; I01 BX002872 United States BX BLRD VA |
| فهرسة مساهمة: | Keywords: Burkholderia; PenA; carbapenemase; cefepime-taniborbactam; β-lactam; β-lactamase inhibitor; β-lactamases |
| المشرفين على المادة: | 807PW4VQE3 (Cefepime) 0 (Anti-Bacterial Agents) 8IGQ156Z07 (taniborbactam) 0 (beta-Lactamase Inhibitors) EC 3.5.2.6 (beta-Lactamases) |
| تواريخ الأحداث: | Date Created: 20230928 Date Completed: 20231216 Latest Revision: 20240129 |
| رمز التحديث: | 20240129 |
| مُعرف محوري في PubMed: | PMC10648927 |
| DOI: | 10.1128/aac.00498-23 |
| PMID: | 37768313 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1098-6596 |
|---|---|
| DOI: | 10.1128/aac.00498-23 |